Dogs and monkeys in preclinical drug development: the challenge of reducing and replacing

@article{Pellegatti2013DogsAM,
  title={Dogs and monkeys in preclinical drug development: the challenge of reducing and replacing},
  author={Mario Pellegatti},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  year={2013},
  volume={9},
  pages={1171 - 1180}
}
  • M. Pellegatti
  • Published 14 August 2013
  • Biology, Medicine
  • Expert Opinion on Drug Metabolism & Toxicology
Introduction: Animal experimentation is a very contentious issue affecting reputation of drug industry. There are several reasons to forecast an increase in the number of dogs and monkeys used in safety and pharmacokinetic studies. This increase may trigger a strong reaction of the public opinion. There have been many proposals and initiatives to change the present approach to safety and metabolic studies. Tests based on new technologies, in vitro cell assays, stem cells, imaging, and… 
Comment on: Dogs and monkeys in preclinical drug development: the challenge of reducing and replacing
  • Jeffrey Brown
  • Biology
    Expert opinion on drug metabolism & toxicology
  • 2013
TLDR
To move preclinical science toward a predictive and effective approach, Dr. Pellegatti’s recommendations should be heard by pharmaceutical companies and applied to all in vivo preclinical studies, and accompanied by diligent agreements to transition away from the use of animals as non-animal approaches are developed.
Dogs as a Natural Animal Model of Epilepsy
  • W. Löscher
  • Biology, Psychology
    Frontiers in Veterinary Science
  • 2022
TLDR
The data presented in this review substantiate that canine epilepsy is an excellent translational model for several facets of epilepsy research, and the development of vagus nerve stimulation as a novel therapy for drug-resistant epilepsy in people was based on a series of studies in dogs with induced seizures.
A practical framework for harmonising welfare and quality of data output in the laboratory-housed dog
x Acknowledgements xiii 1 The use of the dog in laboratories for research and testing 1 1.

References

SHOWING 1-10 OF 89 REFERENCES
Juvenile animal testing in drug development--is it useful?
  • P. Baldrick
  • Biology
    Regulatory toxicology and pharmacology : RTP
  • 2010
Preclinical in vivo ADME studies in drug development: a critical review
  • M. Pellegatti
  • Biology
    Expert opinion on drug metabolism & toxicology
  • 2012
TLDR
The focus of this paper is on some ‘traditional' in vivo ADME studies: excretion balance, metabolic profile and WBA in the toxicological species and their value in the perspective of the contemporary drug development process.
The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates.
Safety evaluation of biological drugs: what are toxicology studies in primates telling us?
  • P. Baldrick
  • Biology, Medicine
    Regulatory toxicology and pharmacology : RTP
  • 2011
Animal models of toxicology testing: the role of pigs
TLDR
This review focuses on the Phase I and Phase II biotransformation pathways in humans and pigs and highlights the similarities and differences of these models.
Considerations Regarding Nonhuman Primate Use in Safety Assessment of Biopharmaceuticals
TLDR
This review summarizes important scientific and regulatory perspectives derived from presentations and audience discussions in an educational forum at the 2010 annual American College of Toxicology meeting regarding opportunities for employing alternative approaches to minimize NHP use in mAb drug development.
Investigative safety science as a competitive advantage for Pharma
TLDR
Why investigative safety science is a competitive advantage for the pharmaceutical industry is outlined and the importance of investigating unanticipated clinical safety signals through a combination of mechanistic preclinical studies and/or molecular characterization of clinical samples from affected organs is emphasized.
Replacing animal experiments: choices, chances and challenges.
TLDR
Systematic reviews of the transferability of animal data to the clinical setting may encourage a fresh look for novel non-animal methods and, as mainstream funding becomes available, more advances in replacement are expected.
Preclinical safety evaluation using nonrodent species: an industry/welfare project to minimize dog use.
This review of the dog, the primary nonrodent species used in toxicology, and its use in the safety evaluation of pharmaceuticals, provides data on the number used in particular projects in an effort
Critical evaluation of the use of dogs in biomedical research and testing in Europe.
TLDR
The report gives an overview on the use of dogs in biomedical research, safety assessment and the drug developmental process and reflects the discussion on theUse of dogs as second (non-rodent)species in toxicity testing.
...
...